✦ LIBER ✦

428 ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIROLOGIC RESPONSE AMONG HEPATITIS C GENOTYPE 1 TREATMENT-NAIVE AND PEG/RIBAVIRIN TREATMENT-FAILURES TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

✍ Scribed by S.C. Gordon; E.J. Lawitz; B.R. Bacon; M.S. Sulkowski; E.M. Yoshida; M. Davis; N. Boparai; V. Sniukiene; M. Burroughs; C.A. Brass; J.K. Albrecht; K.R. Reddy

Book ID: 117379573
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 178 KB
Volume: 54
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(11)60430-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

466 PREDICTORS OF SUSTAINED VIROLOGIC RE

466 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR)

✍ K.R. Reddy; S. Bruno; L. Rossaro; N. Ravendhran; M.P. Pauly; N. Boparai; V. Sniu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

481 FOUR-WEEK THERAPY WITH PEGINTERFERON

481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

✍ J.M. Vierling; E.J. Lawitz; F. Poordad; M.S. Sulkowski; M. Bourliere; M. Buti; C 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

484 PREDICTORS OF SUSTAINED VIROLOGIC RE

484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

✍ S. Zeuzem; J.M. Vierling; R. Esteban; A.L. Gibas; S. Pol; N. Boparai; M. Burroug 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 56 KB

448 RESPONSE-GUIDED THERAPY WITH BOCEPRE

448 RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1

✍ M.P. Manns; F. Poordad; B.R. Bacon; S. Bruno; R. Esteban; M. Silva; M. Buti; M. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 114 KB

452 EFFICACY AMONG NORTH AMERICAN AND EU

452 EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

✍ P. Marcellin; J.M. Vierling; L. Alric; M. Pirisi; A. Tran; J.K. Albrecht; C.A. B 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

522 Combination therapy with peginterfer

522 Combination therapy with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR)

✍ O. Weiland; M.W. Fried; S.J. Hadziyannis; G.R. Foster; D. Messinger; K. Freivoge 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 62 KB